Human Albumin Market is expected to reach US$ 6.98 Billion by 2031

Therapeutic Applications Segment Drives Human Albumin Market Growth

According to our new research study named "Human Albumin Market Forecast to 2031 – Global Analysis – by Source, Application, and End User," the market was valued at US$  4.68 billion in 2024 and is projected to reach US$ 6.98 billion by 2031; it is expected to register a CAGR of 6.0% during 2025–2031. The rising prevalence of chronic diseases, advancements in biotechnology, and soaring demand in biopharmaceuticals are key factors driving the human albumin market size. However, the high production costs, regulatory challenges, supply chain limitations, plasma dependency, ethical concerns, and safety risks hinder market growth. Sustainable and plant-based production, integrating nanomedicine advancements in biopharmaceuticals, is projected to bring new human albumin market trends in the coming years.

According to the World Health Organization (WHO), by 2050, chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory illnesses are projected to account for 86% of global deaths; this is a staggering 90% increase since 2019. Aging populations, lifestyle changes, and rising obesity rates are some of the primary reasons. A recent UNICEF report, published in September 2025, highlights that obesity among children and adolescents has tripled since 2000, now affecting approximately 188 million youths worldwide.

Human Albumin Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

Data from the Centers for Disease Control and Prevention (CDC) indicates that, in 2023, 76.4% of adults in the US reported at least one chronic condition, with 51.4% experiencing multiple chronic conditions. This trend highlights the growing demand for medical treatments, including Human Albumin-based therapies. Therapeutic human albumin is essential for managing hypoalbuminemia, which often occurs in chronic liver diseases and nephrotic syndrome. It also plays a vital role in fluid resuscitation for burn patients in critical care settings.

Human Albumin Market Analysis Based on Segmental Evaluation:  

Based on application, the human albumin market is divided into therapeutic applications, drug delivery, disease diagnostics, research, and others. The therapeutic applications segment held a significant share in 2024. Therapeutic applications include the treatment of liver and kidney diseases, surgery support, hypovolemia, and hypoalbuminemia. Human Albumin maintains blood volume and balances plasma proteins, making it essential in critical care and surgical settings. Its therapeutic uses are divided into liver and kidney diseases, surgery, hypovolemia and hypoalbuminemia, and other conditions.

Based on end user, the human albumin market is categorized into hospitals and clinics, pharmaceutical and biotechnological companies, research institutes, diagnostic laboratories, home care settings, and others. The hospitals and clinics segment held a significant human albumin market share in 2024. Hospitals and clinics are the main users of human albumin because of their high demand in emergency care, surgeries, and managing chronic diseases. human albumin is used for fluid replacement, protein restoration, and other treatments. It is steadily consumed, highlighting its important role in the healthcare systems.

The geographical scope of the Human Albumin market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. North America dominated the human albumin market share in 2024. An advanced healthcare infrastructure, rising prevalence of chronic diseases, and growing demand for plasma-derived therapies drive the human albumin market growth in North America. The US leads the region, supported by a well-established biopharmaceutical sector, extensive plasma collection networks, and strong R&D investments in drug delivery and recombinant technologies.

One of the key drivers is the increasing use of human albumin in critical care for conditions such as liver cirrhosis, nephrotic syndrome, burns, trauma, and hypoalbuminemia. The region's hospitals and emergency care units use human albumin extensively for fluid resuscitation and blood volume restoration. Additionally, the region’s high surgical volume and aging population contribute to increased therapeutic applications of human albumin.

Recombinant human albumin is gaining traction in North America due to growing concerns over disease transmission through plasma-derived products. This shift supports innovation and drives investment in safer, animal-free production technologies.

Regulatory support from the FDA for novel human albumin-based formulations, combined with the strong market presence of key players such as Grifols, CSL, and Takeda, enhances product accessibility. Canada and Mexico are expanding their healthcare services, contributing to regional demand. Overall, clinical need, biotechnological advancement, and healthcare spending are key factors driving the North America human albumin market growth.

CSL Ltd, Grifols SA, Taibang Bio Group Co. Ltd., Merck KGaA, Octapharma AG, HiMedia Laboratories Pvt Ltd, Takeda Pharmaceutical Co Ltd, Thermo Fisher Scientific Inc, InVitria, Biotest AG., Medxbio Pte Ltd, Lazuline Biotech Private Limited, Cyagen Biosciences, Sartorius AG, Aspira Chemical, Lee BioSolutions, Reliance Life Sciences Private Limited, Kedrion SpA, Biorbyt Ltd., and Akron Biotech are among the leading companies profiled in the human albumin market report.

Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com